FOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection

Stock News04-30 16:30

FOSUN PHARMA (600196.SH) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Sodium Nitroprusside Injection. The approved indications for the injection are (1) hypertensive emergencies, such as hypertensive crisis, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension during the perioperative period of pheochromocytoma; it may also be used for controlled hypotension during surgical anesthesia. (2) Acute heart failure, including acute pulmonary edema, as well as acute heart failure associated with acute myocardial infarction or valvular (mitral or aortic) insufficiency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174617856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 16:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174617856","market":"hk","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Sodium Nitroprusside Injection. The approved indications for the injection are (1) hypertensive emergencies, such as hypertensive crisis, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension during the perioperative period of pheochromocytoma; it may also be used for controlled hypotension during surgical anesthesia. (2) Acute heart failure, including acute pulmonary edema, as well as acute heart failure associated with acute myocardial infarction or valvular (mitral or aortic) insufficiency.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-30 16:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Sodium Nitroprusside Injection. The approved indications for the injection are (1) hypertensive emergencies, such as hypertensive crisis, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension during the perioperative period of pheochromocytoma; it may also be used for controlled hypotension during surgical anesthesia. (2) Acute heart failure, including acute pulmonary edema, as well as acute heart failure associated with acute myocardial infarction or valvular (mitral or aortic) insufficiency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1174617856","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174617856","pubTimestamp":1777537818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0239":"医药制造","BK0183":"MSCI概念","BK0096":"民营医院","BK1515":"抗疫概念","BK1191":"制药","BK1593":"医美概念股","BK0188":"融资融券","02196":"复星医药","BK0175":"白马股","BK0012":"证金概念","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队"},"translate_title":"复星医药子公司硝普钠注射液获监管批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Sodium Nitroprusside Injection. The approved indications for the injection are (1) hypertensive emergencies, such as hypertensive crisis, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension during the perioperative period of pheochromocytoma; it may also be used for controlled hypotension during surgical anesthesia. (2) Acute heart failure, including acute pulmonary edema, as well as acute heart failure associated with acute myocardial infarction or valvular (mitral or aortic) insufficiency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174617856","isCrawlerRequest":true}